532523 and NSE Related Headlines
Go Back- Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
- Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
532523 and NSE Related Press Releases
Go Back- Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
- Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
